FindTrial
Sign In

Elironrasib

DRUG2 trials

Sponsors

Revolution Medicines, Inc.

Conditions

Advanced Solid TumorsCRCColorectal CancerColorectal Cancer (CRC)Metastatic Solid TumorsNSCLCNon-Small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer (NSCLC)

Phase 1

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingNCT06128551
Revolution Medicines, Inc.Colorectal Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma
Start: 2023-11-14End: 2029-06-01Target: 534Updated: 2026-02-10
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
RecruitingNCT07397338
Revolution Medicines, Inc.Advanced Solid Tumors, Colorectal Cancer (CRC), CRC +3
Start: 2026-01-30End: 2029-05-01Target: 370Updated: 2026-03-30

Related Papers

Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
Journal of Medicinal Chemistry2025-03-0832 citations
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
Journal of Medicinal Chemistry2025-02-2422 citations